Shude Cui

机构：Henan Cancer Hospital

发表论文 6 篇 · 总被引 36 次 · h-index 2

代表论文

• Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial (2024 · Nature Communications · 被引 32)
• Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial (2025 · Clinical Drug Investigation · 被引 2)
• Abstract P4-03-31: Lifestyle factors are associated with breast cancer risk in women biopsied for benign breast diseases in China: 10-year results of a multi-center, hospital-based, case-control study (2023 · Cancer Research)
• Abstract PD18-03: Final analysis of the Phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer (2023 · Cancer Research)
• Addendum: Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women (2020 · Frontiers in Endocrinology)
• Relationship of Lifestyle Habits to Health-Related Quality of Life of Recently Diagnosed Breast Cancer Between Younger and Older Women in China (2020)